Castle Biosciences (CSTL) EPS (Weighted Average and Diluted) (2018 - 2025)
Castle Biosciences (CSTL) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.07 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) fell 121.88% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.84 through Dec 2025, down 235.48% year-over-year, with the annual reading at -$0.83 for FY2025, 233.87% down from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.07 in Q4 2025 for Castle Biosciences, down from -$0.02 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.32 in Q4 2024 to a low of -$1.1 in Q1 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.31 across 5 years, with a median of -$0.21 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 1066.67% in 2023 and later surged 455.56% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.25 in 2021, then crashed by 216.0% to -$0.79 in 2022, then surged by 88.61% to -$0.09 in 2023, then surged by 455.56% to $0.32 in 2024, then tumbled by 121.87% to -$0.07 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for CSTL at -$0.07 in Q4 2025, -$0.02 in Q3 2025, and $0.15 in Q2 2025.